市場調查報告書
商品編碼
1445530
全球導管相關血流感染(CRBSI)市場評估:按藥物類別、治療、來源、分銷管道和地區劃分的機會和預測(2017-2031年)Catheter-Related Bloodstream Infection Market Assessment, By Drug Class, By Treatment, By Source of Infection, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F |
全球導管相關血流感染 (CRBSI) 市場規模將從 2023 年的 17.1 億美元增長到 2031 年的 25 億美元,2024-2031 年預測期間複合年增長率為 5.35%。預計將增長到9000萬美元。
市場成長的驅動因素是世界不同地區侵入性醫療程序數量的增加、人口老化的加劇、慢性病盛行率的增加。
越來越多地採用先進產品和技術(例如增強型診斷方法和抗菌塗層導管)來預防和治療 CRBSI,為市場提供了利潤豐厚的成長機會。 CRBSI 的長期挑戰是推動尖端解決方案的開發。 不當的滅菌方法和不斷增加的醫院感染盛行率是推動市場需求的一些主要因素。 研究機構和主要參與者越來越關注開發促進患者安全的先進產品,這進一步支持了市場擴張。
增加與 CRBSI 相關的研究活動
正在進行各種研究活動和調查,以了解與這種疾病相關的各種併發症並追蹤 CRBSI 並最終減少病例數。 2023年,在加納一家三級醫院進行的一項橫斷面研究發表,旨在確定維持性血液透析患者中□□與CRBSI相關的因素,觀察到CRBSI的盛行率很高。
參與公司加強開發新療法
各個主要參與者正在努力開發 CRBSI 的治療和預防解決方案。 2023 年,CorMedix, Inc. 的 DefenCath 獲得 FDA 批准。 這種含有肝素和牛磺羅定的導管封管溶液有助於治療和預防接受中心靜脈導管慢性血液透析的成人的 CRBSI。 DefenCath 是水性、無菌、透明且不含防腐劑的,是美國核准的第一個也是唯一一個抗菌封管液。
北美佔較大市佔率
該地區的市場擴張是由於老年人口的不斷增長、導管插入術的需求不斷增加、醫療基礎設施的完善以及血液相關感染治療技術的快速進步。 根據人口參考局的數據,從 2022 年到 2050 年,65 歲及以上的美國人數量預計將增加 47%。 預計這一數字將從5,800萬人(2022年)增加到8,200萬人(2050年),65歲及以上人口比例預計將從17%增加到23%。
本報告調查了全球導管相關血流感染(CRBSI) 市場,並提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構和市場成長。它總結了影響因素的分析因素、案例研究、競爭格局和主要公司概況。
Global catheter-related bloodstream infection market is projected to witness a CAGR of 5.35% during the forecast period 2024-2031, growing from USD 1.71 billion in 2023 to USD 2.59 billion in 2031F. The market growth is driven by a rise in the number of invasive medical procedures, an increasing aging population, and a growing prevalence of chronic diseases in various regions across the globe.
The rising adoption of advanced products and technologies for the prevention and treatment of catheter-related bloodstream infections, including enhanced diagnostic methods and antimicrobial-coated catheters, is providing lucrative growth opportunities for the market. The long-posed challenges of catheter-related bloodstream infections are prompting the development of cutting-edge solutions. The increasing incidence related to improper aseptic procedures and the growing prevalence of hospital-acquired infections are some of the major factors bolstering the market demand. The increasing emphasis of research organizations and major market players on the development of advanced products that promote patient safety is further supporting the market expansion.
According to a ScienceDirect article, in the Elsevier Journal in December 2023, a team of researchers and The Flume Catheter Company, in the United Kingdom is working on the development and testing of a FLUME urinary catheter with relocated drainage holes and protected tip. The retaining balloon supports a static load of 700 grams and reduced trauma when forced evulsion was modeled. The catheter design aims to enhance patient safety and comfort while maximizing bladder drainage.
Increasing Research Activities on CRBSI
Various research activities and studies are being conducted to understand the different complications associated with the disease and track CRBSI to ultimately reduce the number of cases. In 2023, a cross-sectional study conducted at a tertiary hospital in Ghana to determine the factors associated with catheter-related bloodstream infections among patients who were on maintenance hemodialysis was published. The cross-sectional hospital-based study was conducted on patients who were receiving maintenance hemodialysis via central venous catheters. The risk factors that were predictive of catheter-related bloodstream infections were determined with the help of multivariate analysis using logistic regression. High prevalence of catheter-related bloodstream infections was noted among patients undergoing hemodialysis. The most common causative agent was Coagulase negative Staphylococci. As per the conclusion of the study, there is a high requirement for infection surveillance units in the renal unit for tracking catheter-related bloodstream infections and taking significant measures to reduce these infections. It was noted that the prevalence of catheter-related bloodstream infections among the participants was 34.2%. A contributing factor for the prevalence of CRBSI in the participants of the study may be the lack of utilization of antiseptic or antibiotic lock system.
Increasing Efforts Towards Development of Novel Treatments by Market Players
Various major market players are dedicated towards developing treatment and prevention solutions for catheter-related bloodstream infections. In 2023, CorMedix, Inc. received FDA approval for DefenCath. The heparin and taurolidine containing catheter lock solution aids in treating and preventing catheter-related bloodstream infections in adults undergoing chronic hemodialysis through a central venous catheter. The aqueous-based, sterile, clear, and preservative-free DefenCath is the first and only antimicrobial catheter lock solution approved in the United States. DefenCath will allow healthcare providers to reduce the risk of infections in patients suffering from underlying kidney failure. The approval of the product was based upon the findings from the Phase 3 LOCK-IT-100 clinical study. The multicentral, randomized, active control, double-blind trial analyzed the safety and efficacy of DefenCath in lowering the incidences of catheter-related bloodstream infections in patients undergoing chronic hemodialysis due to kidney failure.
North America Accounts for a Significant Market Share
The expansion of the market in the region can be attributed to the growth of the geriatric population, increased requirement for catheters insertion, presence of a well-established healthcare infrastructure and rapid technological advancements for treatment of blood related infections. According to the Population Reference Bureau, the number of Americans aging 65 years and older is estimated to witness a 47% increase from 2022 to 2050. The number is projected to increase from 58 million (in 2022) to 82 million (by 2050). The share of the 65-and-older age group is expected to increase from 17% to 23%.
Frequent catheterization is often required in the elderly if they are suffering from urinary retention, continence, cancer, and pressure ulcers, increasing the risk of catheter-related bloodstream infections. Long-term catheterization is preferred by various caretakers and healthcare professionals as it reduces their burden and allows them to focus on the other requirements of the patient. However, catheterization for long intervals of time can often lead to complications and cause catheter-related bloodstream infections.
Increasing Research Activities on Coagulase-Negative Staphylococcus Support Segment Growth
Undergoing research activities are expected to determine how to effectively manage catheter-related bloodstream infection caused by coagulase-negative staphylococcus. As per the clinical guidelines, the management of coagulase-negative staphylococcus causing catheter-related bloodstream infections requires antibiotic treatment for five to seven days along with catheter removal. According to an Antibiotics article published in May 2023, in National Library of Medicine, randomized clinical trials are being conducted with the aim to determine whether no administration of antibiotic therapy is effective and safe in low-risk episodes of catheter-related bloodstream infections caused by coagulase-negative staphylococcus. In the study, the patients suffering from CRBSI caused by coagulase-negative staphylococcus were randomized 1:1 after the withdrawal of catheter were opted to receive or not receive parenteral antibiotics that act against the isolated strain. The secondary endpoints of the study were septic embolism, persistent bacteremia, time until the disappearance of the fever, and time until microbiological cure. The primary endpoint was the occurrence of any complications related to the antibiotic therapy or bacteremia within the ninety days of the follow-up.
Online Pharmacies Expected to Witness Significant Growth Over the Forecast Period
Owing to the convenience offered by online pharmacies, including fast deliveries, this distribution channel has evolved from an alternative method for procuring medication and has gained immense popularity. Over the past few years more patients have recognized the convenient nature of shopping across these pharmacies, supplanting the reliance on retail pharmacies. According to a survey funded by Sanofi Consumer Healthcare, respondents indicated various advantages of online pharmacies including reduced costs for patients, convenience, and increased access for patients.
Online pharmacies eliminate the requirement of calling in a prescription, walking or driving to the pharmacy and waiting in line. The unparalleled levels of confidentiality and privacy offered by online pharmacies is further boosting the popularity of the distribution channel. The growth of the segment is facilitated by the rapid expansion of the internet services and ease of mail-order trade. Furthermore, the price transparency and accessibility offered by online pharmacies is encouraging consumers to adopt these channels for purchasing different medication.
Future Market Scenario (2024 - 2031F)
The catheter-related bloodstream infection (CRBSI) market is expected to witness significant growth in the coming years due to several factors including increasing emphasis on research and development activities and growing requirement for catheters in elderly patients.
The rising investments towards the healthcare and pharmaceutical industries is expected to offer lucrative growth opportunities to the market.
Various studies are being conducted to examine the risk of catheter-related bloodstream infections in patients with hemodialysis catheters. For instance, Zealand University Hospital is conducting an interventional study to examine the effects of ethanol (70%) as a lock solution. The study is estimated to conclude in April 2025.
University of Zurich is on the phase 4 of their interventional study aiming to understand the effect of vancomycin after catheter replacement. The randomized controlled trial will study the effect of a single dose of vancomycin on infection resolution after the replacement of catheter for suspected central line-associated bloodstream infection. The study is expected to conclude in December 2024.
Key Players Landscape and Outlook
Key participants in the catheter-related bloodstream infection market include Pfizer Inc., Citius Pharmaceuticals, Inc., Glenmark Pharmaceuticals Ltd., CorMedix, Inc., and Teva Pharmaceuticals. Increasing research and development activities and strategic partnerships between leading market players is expected to offer lucrative growth opportunities to the market.
In 2023, CorMedix, Inc. received FDA approval for DefenCath. According to FDA, the drug will reduce incidences of catheter-related bloodstream infections in adults receiving chronic hemodialysis via a central catheter due to kidney failure.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work